You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

Pediatrics/Children's Health Trials

Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.

Page 1 of 1 | Results 1 - 5 of 5

A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates

The study will be conducted in two parts. Part A will determine the safety and tolerability of two doses of the study drug, STP206, versus control. Part B will evaluate the safety and efficacy of the study drug, STP206, in very low and extremely low birth weight neonates for prevention of Necrotizing Enterocolitis (NEC).
Dr. Rachana Singh
Pediatrics

Baystate Medical Center 759 Chestnut Street Springfield, MA 01199

Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects with Type 2 Diabetes Mellitus Protocol # WEL-A-U307

The purpose of this study is to evaluate the safety and tolerability of Welchol® (colesevelam HCl) as a treatment for children/adolescents with Type 2 Diabetes.

Holley Allen, MD, MSPH
Pediatrics, Diabetes

Baystate Children's Specialty Center
50 Wason Ave
Springfield, MA

Efficacy of Recombinant Human Clara Cell 10 KDA Protein (CC10) Administered to Premature Neonates with Respiratory Distress Syndrome

Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infants characterized by marked inflammation and alveolar hypoplasia.  Presently there are no known medications which prevent the development of BPD.   The purpose of the present study is to evaluate the ability of a single intratracheal dose of recombinant human CC10 to prevent the development of long-term respiratory complications and BPD in ventilated premature infants. 

Dr. Jeffrey Shenberger
Pediatrics

Baystate Medical Center 759 Chestnut Street Springfield, MA 01199

Improving Outcome in Neonatal Abstinence Syndrome

The purpose of this research study is to compare treatment options for infants with Neonatal Abstinence Syndrome (NAS) due to narcotic exposure in the womb and evaluate the effects of treatment on long-term neurodevelopmental outcome at 18 months of age. The goal is to compare the two most commonly used drugs and see which requires fewer days in the hospital to complete treatment.  The study will also determine if genetic variations contribute to the severity of NAS.

Jeffrey Shenberger, MD
Pediatrics

Baystate Children's Hospital
759 Chestnut Street
Springfield, MA 01199

The 4 C program The Massachusetts Alliance for Complex Care Collaborative Consultative Care Coordination Program (MACC/4C)

Information gathered will be used to create a Comprehensive Care Plan available to families and providers on a secure Internet portal. The child’s pediatrician will have access to a support team lead by a Nurse Care Coordinator with the help of a Social Worker and Family Navigator to the family to address behavioral health issues, link families to community resources, help them overcome barriers to care, and coordinate among multiple agencies and benefits. In addition to collaborate care coordination, the pediatricians in the community will have access to the expert consultation of Complex Care Pediatricians, Developmental/Behavioral Specialists, Nutritionists, and Psychiatrists.
Sadof, Matthew, MD
Pediatrics

BMC Springfield Locations

Page 1 of 1 | Results 1 - 5 of 5